Larry Papasan - H CYTE Independent Chairman of the Board
Chairman
Mr. Larry W. Papasan is CoChairman of the Board of Medovex Corporationration From July 1991 until his retirement in May 2002, Mr. Papasan has served as Chairman of the board of directors of the Company since September 2013. From July 1991 until his retirement in May 2002, Mr. Papasan served as President of Smith Nephew Orthopedics. He was a Director and Chairman of the board of directors of BioMimetic Therapeutics, Inc. NasdaqGMBMTI since August 2005. BioMimetic Therapeutics is developing and commercializing bioactive recombinant proteindevice combination products for the healing of musculoskeletal injuries and disease, including orthopedic, periodontal, spine and sports injury applications. since 2016.
| Age | 76 |
| Tenure | 8 years |
| Phone | 844-633-6839 |
| Web | http://www.MedoveX.com |
H CYTE Management Efficiency
The company has return on total asset (ROA) of (65.35) % which means that it has lost $65.35 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (171.59) %, meaning that it created substantial loss on money invested by shareholders. H CYTE's management efficiency ratios could be used to measure how well H CYTE manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 1.92 M in liabilities with Debt to Equity (D/E) ratio of 21.0, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. H CYTE Inc has a current ratio of 0.91, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist H CYTE until it has trouble settling it off, either with new capital or with free cash flow. So, H CYTE's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like H CYTE Inc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for MDVX to invest in growth at high rates of return. When we think about H CYTE's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 13 records | CHAIRMAN Age | ||
| Zhu Yanfeng | United Guardian | 54 | |
| Louis Gallois | United Guardian | 71 | |
| Jon Moeller | Procter Gamble | 60 | |
| Alan Lafley | Procter Gamble | 67 | |
| David Taylor | Procter Gamble | 62 | |
| Thomas Florsheim | Weyco Group | 66 | |
| MarieHelene PeugetRoncoroni | United Guardian | 54 | |
| Kenneth Globus | United Guardian | 66 | |
| Flemming Ornskov | Waters | 62 | |
| Carlos Tavares | United Guardian | 56 | |
| Christopher OConnell | Waters | 51 | |
| Robert Thornton | SunLink Health Systems | 75 | |
| Douglas Berthiaume | Waters | 66 | |
Management Performance
| Return On Equity | -171.59 | |||
| Return On Asset | -65.35 |
H CYTE Inc Leadership Team
Elected by the shareholders, the H CYTE's board of directors comprises two types of representatives: H CYTE inside directors who are chosen from within the company, and outside directors, selected externally and held independent of MDVX. The board's role is to monitor H CYTE's management team and ensure that shareholders' interests are well served. H CYTE's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, H CYTE's outside directors are responsible for providing unbiased perspectives on the board's policies.
| John Blank, Director | ||
| Randal Betz, Director | ||
| James Andrews, Director | ||
| Scott Haufe, Independent Director | ||
| Briley Cienkosz, Chief Marketing Officer | ||
| Clyde Hennies, Independent Director | ||
| Jeremy Daniel, CFO | ||
| Larry Papasan, Independent Chairman of the Board | ||
| Thomas Hills, Independent Director | ||
| Charles Farrahar, Secretary | ||
| Patrick Kullmann, President COO | ||
| Steven Gorlin, Director | ||
| Jason Assad, IR Contact Officer | ||
| Ann Miller, COO | ||
| Gary Mancini, Chief Relationship Officer | ||
| Michael Yurkowsky, Director | ||
| Dennis Moon, Executive VP | ||
| Jarrett Gorlin, CEO and Director | ||
| Ron Lawson, Director | ||
| William Horne, Chairman of the Board, CEO | ||
| Jon Mogford, Director | ||
| Raymond Monteleone, Director | ||
| John Thomas, Independent Director | ||
| Jesse Crowne, Executive Co-Chairman of the Board | ||
| Jeffery Wright, CFO |
MDVX Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is H CYTE a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -171.59 | |||
| Return On Asset | -65.35 | |||
| Operating Margin | 976.89 % | |||
| Current Valuation | 37.71 M | |||
| Shares Outstanding | 98.89 M | |||
| Shares Owned By Insiders | 4.26 % | |||
| Shares Owned By Institutions | 0.02 % | |||
| Number Of Shares Shorted | 253.31 K | |||
| Price To Earning | (2.09) X | |||
| Price To Book | 3.99 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in real. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Other Consideration for investing in MDVX OTC Stock
If you are still planning to invest in H CYTE Inc check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the H CYTE's history and understand the potential risks before investing.
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity |